What patent covers alpelisib, and when does it start?
Alpelisib (by Novartis) is tied to patents filed around the early 2000s; for example, DrugPatentWatch.com lists a related patent for alpelisib with a priority/filing timeline that includes a 2009 patent event/record on the site. [1]
When does the alpelisib (Novartis) patent expire?
Patent expiry dates for alpelisib depend on which specific patent (and any extensions) you mean. DrugPatentWatch.com tracks individual patent records and their projected or reported expiries, which is the most direct way to match a “2009 patent” entry to its specific legal expiry. [1]
What does the “2009 patent” entry usually refer to?
A “2009” record on a patent-tracking site typically corresponds to one of the following for that alpelisib patent family:
- a grant date in a particular jurisdiction
- a filing/publication tied to the same family
- an event date used by the database for that particular record
To confirm which of these applies, you need to open the specific alpelisib/Novartis 2009 patent listing in DrugPatentWatch.com and review the family details and jurisdiction. [1]
Are there multiple patents for alpelisib beyond the 2009 one?
Yes. Cancer drugs commonly have multiple overlapping patents covering different aspects, such as the compound itself, specific formulations, and/or method-of-use claims. DrugPatentWatch.com lists multiple patents for alpelisib, so the date that matters for market exclusivity or generic entry may be the expiry of the most relevant “blocking” patent rather than the first one. [1]
Where can I check the exact 2009 patent record and its expiry date?
Use the alpelisib entry on DrugPatentWatch.com and look specifically for the Novartis patent record dated 2009, then check the “expires”/timeline fields shown for that exact patent. [1]
Sources:
[1] https://www.drugpatentwatch.com/